Alloksys and AMRIF appoints Koos van Haasteren as CEO to gear up for RESCAP® platform development
Utrecht, 28 December 2015 – The Dutch based Alloksys Life Sciences BV and AMRIF BV have expanded their Management teams to gear up for stage 3 Clinical Trials of their therapeutic compound RESCAP® (Rescuing Alkaline Phosphatase).
Per 1st November 2015, drs. Koos van Haasteren has been appointed CEO of both companies. Mr van Haasteren (Leiden, the Netherlands, 1960) has worked at SABIC, DSM and KPMG and has a track record of successfully creating sustainable business growth and leading global operations.
Ruud Brands PhD will remain President of the Board of Executive Directors in both Alloksys and AMRIF. He will continue to focus on the successful completion of the stage 3 clinical trials for open heart surgery and kidney transplants at Alloksys and several promising therapeutic applications in chronic diseases at AMRIF. Mr. Brands has been at the cradle of the foundation of both companies and has a track record of successful development of therapeutics. “With this step we further strengthen the leadership teams for successful development of the full potential of our promising RESCAP® platform for both acute clinical settings and chronic diseases” says Ton Bolier, MD, Chairman of the Supervisory Board of both companies.
About Alloksys and AMRIF Alloksys Life Sciences BV (founded 2006, based in Utrecht, the Netherlands) is developing the RESCAP® platform as an anti-inflammatory compound in acute clinical settings like open heart surgery, organ transplants and severe burn wounds. AMRIF BV (founded 2013, based in Wageningen, the Netherlands) has developed a highly effective recombinant human RESCAP (RESCAP®) with superior pharmaco-kinetic specifications as a cure for a large variety of chronic diseases. Contact For more information on this press release, please contact: Mr. Ruud Brands PhD +31(0)30 253 3615 +31(0)6 47 22 83 95 email@example.com